NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Attorney Advertising Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICU Medical, Inc. ("ICU Medical" or "the Company") (NASDAQ:ICUI). Investors who purchased ICU Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICUI.

Investigation Details

On April 22, 2025, ICU Medical received a warning letter from the Food and Drug Administration ("FDA"). According to the FDA, the Company "made multiple changes to the Medfusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices." The FDA states that the Company's pumps were "adulterated" and "misbranded," with modifications that "can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device's risk profile." Following this news, ICU Medical stock dropped.

What's Next?

If you are aware of any facts relating to this investigation or purchased ICU Medical securities, you can assist this investigation by visiting the firm's site: bgandg.com/ICUI. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire